CD19 and precursor B-cell acute lymphoblastic leukemia: The CD19/CD3-bispecific T-cell engager antibody Blinatumomab is a successful example of antibody-based T-cell treatment with the potential to induce long-term clinical benefits in patients with refractory B-ALL [8, 10, 11].